Oxford BioMedica has expanded an existing licence agreement for its LentiVector technology with a major multinational pharmaceutical company
The amendment broadens the agreement from an annual license for use of Oxford BioMedica's gene delivery technology for research activities in the USA to a world-wide perpetual license.
Under the terms of the amended agreement, Oxford BioMedica will receive a one-time undisclosed payment from the licensee.
Oxford BioMedica's lentivirus-based gene delivery technology, known as LentiVector, is said to be one of the most powerful technologies for the delivery of genes to a wide range of cell and tissue types.
The LentiVector technology has applications both in therapeutic products and as a drug discovery tool for target validation and the creation of targeted disease models.
Oxford BioMedica has a comprehensive portfolio of US and European patents that cover the technology.
The company has an active licensing programme providing access to its LentiVector technology on a non-exclusive basis primarily.
Licensees include Biogen Idec, Merck, and Pfizer.
